key: cord-0806130-13kn5x3n authors: Kaye, Alan D.; Okeagu, Chikezie N.; Tortorich, Gregory; Pham, Alex D.; Ly, Eric I.; Brondeel, Kimberley C.; Eng, Matthew R.; Luedi, Markus M.; Urman, Richard D.; Cornett, Elyse M. title: COVID-19 impact on the renal system: pathophysiology and clinical outcomes date: 2021-03-02 journal: Best Pract Res Clin Anaesthesiol DOI: 10.1016/j.bpa.2021.02.004 sha: 42fd2f7885ca1cea49dd6ec6c0371221871aa357 doc_id: 806130 cord_uid: 13kn5x3n COVID-19 has numerous deleterious effects throughout the body. Prior studies had shown that the incidence of acute kidney injury in COVID-19 patients could be as high as 25%. There are also autopsy reports showing evidence of viral tropism to the renal system. In this regard, COVID-19 can damage the kidneys and increase a patient's risk of requiring dialysis. Available evidence suggests that renal involvement in COVID-19 infection is not uncommon, and there has been an increased incidence of chronic kidney disease related to the pandemic. In this present review, we address COVID-19 and its effects on the renal system, including the pathophysiologic mechanisms. We also address current studies on the causes of injury to the renal system, the cause of kidney failure, its effect on mortality, the impact on dialysis patients, and the impact on renal transplant patients. COVID-19 disease may have unique features in individuals on chronic dialysis and kidney transplant recipients, requiring increased vigilance in limiting viral transmission in perioperative, in-patient, and dialysis center settings. Since the first case discovered in Wuhan, China, in 2019, there have been over 5 million confirmed cases of COVID-19 and over 300,00 deaths as of May 25 th , 2020, with rapid expansion into over 150 countries (1, 2) . Initially, common symptoms were presented (usually 2-14 days after exposure), including fatigue, dry cough, fever, sore throat, diarrhea, and dyspnea (1, 2) . Patients had shown bilateral ground-glass opacities on Computerized Tomography (CT) scan revealing lung pathology, which contributed to the thought that COVID-19 predominantly affected the respiratory system (1) . As investigations continued, new reports emerged that COVID-19 was not solely restricted to the respiratory system but impacted numerous others, including the nervous system, immune system, hematology, cardiac system, gastrointestinal system, and kidneys (1) . Prior studies had shown that the incidence of acute kidney injury in COVID-19 patients was speculated to be as high as 25% (3) . There were also autopsy reports showing evidence of viral tropism to the renal system. It was also shown that 60% of 147 patients with COVID-19 had experienced proteinuria, with 48% experiencing hematuria (3) . Lab values had demonstrated that patients experienced increased BUN and creatinine (3) showing further evidence of renal insult. Understanding the impact of COVID-19 on the renal system is tantamount as acute kidney injuries (AKI) may be associated with increase mortality, particularly for patients that require escalating treatment such as renal replacement therapy (3) . In this manuscript, we discuss COVID-19 and its impact on the renal system. We also describe current research on diagnosing covid-19 related kidney dysfunction, the mechanism of injury to the renal system, its cause of kidney dysfunction and effect on mortality, the impact on dialysis patients and renal transplant patients, and current treatments. J o u r n a l P r e -p r o o f cells of the lung, GI tract, and kidneys. Electron microscopic examination revealed clusters of coronavirus particles with distinctive spikes in the tubular epithelial cells and podocytes. ACE2 expression was upregulated in patients with COVID-19 infection, amplifying the direct viral injury to kidneys. The proximal tubules were found to be the most severely damaged portion of the renal tubules (6) . Severe inflammation is a known trigger for AKI in many different disease states. Interestingly, COVID-19 most closely represents the inflammatory pattern of hemophagocytic lymphohistiocytosis. The complement cascade is an important component of our innate immune system that rapidly responds to pathogens. Dysregulation of this complement system can have detrimental effects, however. Overactivation of the complement system notably injures the lungs, which is a known risk factor in AKI development. There is some evidence for anti-complement C5a blocking antibodies to reduce lung damage and combat COVID-19's effects. Levels of ferritin, IL-6, CRP, platelets, and d-dimer are seen in severe COVID-19 cases and can be used to measure the severity of illness. This finding suggests the importance of inflammation in the damage and fatality driven by COVID-19 infections (6). Vascular injury is another major driver of kidney injury in COVID-19. Widespread endothelial damage caused directly by viral particles and inflammatory molecules causes a decrease in vasodilatory agents such as nitrous oxide (NO). This causes an increased response to vasopressor support and an imbalance in constriction versus dilation. This overwhelming constriction causes decreased renal perfusion, creating a pre-renal azotemia. This endothelial damage also causes activation of the coagulation cascade. The combined effect of vasoconstriction and increased thrombus formation causes further microvascular damage, a key J o u r n a l P r e -p r o o f component to kidney damage. This overconsumption of coagulation factors can lead to Diffuse Intravascular Coagulation (DIC), which is seen in 71% of non-survivors (6) . With all these devastating factors affecting the kidneys, management of AKI in COVID-19 is extremely difficult. The best management strategy includes early detection, appropriate volume resuscitation, avoidance of nephrotoxic agents, managing metabolic and electrolyte abnormalities, and beginning renal replacement therapy when appropriate (6) . Available evidence suggests that renal involvement in COVID-19 infection is not uncommon. Hallmarks of kidney injury such as proteinuria, hematuria, and elevated BUN and creatinine have been observed in up to 60% of affected patients (7) (8) (9) . Furthermore, post mortem studies of patients who died with COVID-19 have revealed elements of renal injury such as acute tubular injury and collapsing glomerulopathy, and the presence of viral particles within both the tubular epithelium and podocytes (10) (11) (12) (13) (14) (15) . As is the case with many aspects of the novel coronavirus, the exact methods by which COVID-19 causes renal injury have not yet been fully elucidated. However, the pathogenesis of kidney injury in COVID-19 appears to be multifactorial, and multiple direct and indirect mechanisms have been implicated (8) (9) (10) . Firstly, current evidence suggests that SARS-CoV-2 may directly affect the kidney via viral tropism. The virus enters cells by binding its spike protein to membrane-bound angiotensinconverting enzyme II (ACE2). ACE2 is highly expressed in the kidneys in renal tubular epithelial cells and podocytes. Additionally, endothelial dysfunction, coagulopathy, and complement activation are likely to play a role in renal injury in COVID-19 infection. J o u r n a l P r e -p r o o f is thought to contribute to kidney injury via these signaling pathways. This method of kidney injury has previously been suggested in the setting of ARDS (10) . Given the novelty of COVID-19, much is still unknown about its effects on different organ systems and the resultant impact on mortality. Current research suggests that renal impairment in COVID-19 is associated with increased mortality. Gasparini et al. conducted a retrospective study of 372 patients hospitalized in the ICU with COVID-19 to investigate the effects of kidney injury on patient outcomes. Kidney injury was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Patients were divided into five categories: those with no kidney injury; those who developed new-onset AKI; those with preexisting CKD; those with ESRD; and those who had previously undergone a renal transplant. Inhospital mortality was examined as the primary outcome, while change in mean creatinine and need for renal replacement therapy (RRT) were examined as secondary outcomes. Of the 372 patients, 168 (45%) developed AKI during their ICU stay. Forty-eight patients (13%) had preexisting renal impairment. The authors found that COVID19 patients with AKI or CKD exhibited greater in-hospital mortality than those with preserved renal function. 107 of the 216 patients with AKI and/or CKD (50%) died in hospital compared to only 32/156 (21%) in the non-AKI group. Mortality rates were comparable when comparing patients with new-onset AKI to patients with pre-existing CKD. The highest mortality was observed in patients who had previously undergone renal transplantation (6/7 patients, 86%). Worsening renal function, as indicated by increased KDIGO stage, was associated with increased mortality. Furthermore, of those who survived, a significant proportion required RRT after discharge (16) . Though limited, these data serve to demonstrate the considerable impact of kidney injury in COVID-19 outcomes. Further investigation is warranted to refine treatment to prevent kidney dysfunction, thereby improving patient mortality. Patients undergoing hemodialysis with COVID-19 require special considerations in medical management. In particular, dialysis patients often carry other comorbidities (hypertension, heart disease, diabetes, etc.) that may impact clinical outcomes for those with COVID-19 (17)(18). Therefore, careful preventative measures remain integral for hemodialysis patients in the perioperative and intensive care setting. Patients presenting with uremia carry weaker immune systems and demonstrate greater fluctuations in infectivity and clinical symptoms (19) . Diagnosis of COVID-19 in hemodialysis patients is integral since AKI is a primary predictor for poor outcomes during a COVID-19 infection (21) . However, the variance in clinical symptoms in this patient subset remains a challenge. In one case series of patients with COVID-19 in Zhongnan Hospital of Wuhan University, diarrhea (80%) was the most common symptom, followed by fever (60%) and fatigue (60%), and lymphopenia occurred in every patient (25) . Xiong et al. demonstrated in a study involving 65 hemodialysis centers that of the 2% of hemodialysis patients who tested positive for COVID-19, nearly 50% exhibited fever, and 20% remained asymptomatic (26) . Furthermore, the high mortality rates amongst hemodialysis patients with COVID-19 indicate the importance of taking special considerations for their medical management. Some studies report a mortality rate that is nearly 30% greater than the COVID-19 general population (26) (27) . Other studies involving the European Dialysis and Transplant Association Registry report a mortality rate for dialysis patients with COVID-19 of approximately 25% (28) (29) . Lastly, in-center hemodialysis centers raise the risk of infection transmission due to their densely populated outpatient units. At one hemodialysis center of Renmin Hospital of Wuhan University, nearly 20% of patients on hemodialysis and 15% of facility workers developed the COVID-19 infection over one month (30) . Therefore, increasing home dialysis utilization, (32) . In summary, the management of these at-risk patients must follow stringent guidelines to reduce the transmission risk to other patients and healthcare workers. Until more data becomes available, managing kidney transplant patients with COVID-19 remain not well understood in the transplant community. In particular, balancing the chronic Instead, providers should on a case-by-case basis carefully reduce dosages of immunosuppressants, such as azathioprine, mycophenolate, and calcineurin inhibitors, while avoiding drug to drug interactions with medications specifically utilized against COVID-19, (37) and consider using low dose methylprednisolone for immunosuppression (38) . In cases where Just as in dialysis patients, mortality rates amongst kidney transplant patients are high. In one study assessing 28-day mortality after a COVID-19 diagnosis, kidney transplant recipients carried a 1.28 times higher mortality as dialysis patients with COVID-19 (41) . In another study involving 305 subjects from the European Renal Association COVID-19 Database, kidney transplant patients with COVID-19 carried a 21% probability of death over 28 days (28) . Kidney involvement in COVID-19 is frequent and clinical presentation can range from mild proteinuria to progressive acute kidney injury (AKI), necessitating renal replacement therapy (42) . Given the substantial kidney involvement in the disease manifestation of COVID-19 and evidence linking kidney function decline to mortality, treatment of COVID-19 related kidney injury is a vital area that needs to be explored further. In a multi-center, retrospective, patients that proteinuria, hematuria, and elevated blood urea nitrogen levels, serum creatinine, uric acid as well as D-dimer were significantly associated with the death of COVID-19 patients. Their data also suggested that COVID-19 patients that developed AKI had a ~5.3 times mortality risk than patients without AKI. The fatality in these conditions should prompt clinicians to employ a high degree of caution in monitoring kidney functions of patients with severe COVID-19 affliction, regardless of their disease history. Additionally, clinicians should consider any potential interventions to protect kidney functions at the early stage of the disease and renal replacement therapies in severely ill patients-particularly those with strong inflammatory reactions or a cytokine storm (43, 44) . To date, there is no specific treatment for COVID-19 induced AKI, and management of COVID-19 associated AKI is generally similar to patients with AKI associated with other etiologies such as sepsis (45, 46) . Current management of COVID-19 associated AKI includes supportive treatment, avoiding nephrotoxic drugs, and, if possible, an early application of renal replacement therapy (47, 48) . Implementation of the Kidney Disease: Improving Global Outcomes (KDIGO supportive care guideline (e.g., avoidance of nephrotoxins, regular monitoring of serum creatinine and urine output, consideration of hemodynamic monitoring) in J o u r n a l P r e -p r o o f critically ill patients with kidney involvement is likely to reduce both occurrence and severity of AKI in COVID-19, but requires validation (42, 49) . Evidence suggests that conservative management of volume overload, metabolic acidosis, and hyperkalemia can be attempted before implementing kidney replacement therapy (KRT). Shaikh et al. describe methods for potentially delaying KRT to conserve valuable resources during hospital surges, including escalating dosages of IV loop diuretics in patients with volume overload, IV sodium bicarbonate solution in patients with severe metabolic acidosis, and use of rapid-acting potassium binders such as sodium zirconium cyclosilicate for hyperkalemia (46) . Careful fluid management is important to consider as a modality to reduce the risk of non-cardiogenic pulmonary edema, commonly associated with ARDS (50) (51) (52) . In the absence of shock and hypotension, fluid conservative therapy is recommended to achieve a negative fluid balance of 0.5-1.0 L per day (47, 52) . Strategies for adjusting fluid balance according to volume responsiveness and tolerance assessment aim to restore normal volume status and prevent volume overload, to reduce the risk of pulmonary edema, right ventricular overload, congestions, and subsequent AKI. It is important to note that patients admitted with COVID-19 can often present with volume depletion due to pyrogenic effects and GI disturbances, and pre-hospital fluid resuscitation is rarely performed. These cases warrant the correction of hypovolemia to prevent AKI (42) . In the presence of shock, fluid balance may be achieved with renal replacement therapy (RRT), especially if there is associated AKI and oliguria (52) . SARS, MERS, and sepsis have been successfully treated in the past with continuous renal replacement therapy (CRRT), as CRRT by hemofiltration and hemodiafiltration can contribute to the improvement of organ failure in these cases. Therefore, CRRT may be J o u r n a l P r e -p r o o f beneficial in patients with COVID-19 and sepsis syndrome, but it needs to be further evaluated carefully considering the logistical limitations during the current pandemic (47) . Unfortunately, well-established RRT programs have struggled due to a lack of machines, supplies, and personnel (53) . The COVID-19 Treatment Guidelines Panel recommends continuous renal replacement therapy (CRRT), if available, for critically ill patients who have AKI and develop indications for RRT. Suppose CRRT is either not available or not possible due to a lack of resources, including equipment and staff. In that case, the Panel recommends prolonged intermittent renal replacement therapy (PIRRT) rather than intermittent hemodialysis (IHD) (54) . The scarcity of resources has necessitated novel approaches to RRT programs, including "sharing" CRRT machines between patients with each patient receiving a daily 10-12 hour session and utilizing peritoneal dialysis-a delivery not traditionally used in North American ICUs for treatment of AKI (53) . Beyond the selection of RRT modalities, the dialysis prescription in COVID-19 associated AKI presents unique considerations, and the ideal ultrafiltration target also remains uncertain. Hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS), both cardinal features of severe COVID-19 cases, can be exacerbated by a fluid accumulation that is subsequently worsened by AKI. The decision to remove fluid via ultrafiltration and how fast to do so is still uncertain as it may present with a trade-off in complications. For example, rapid fluid removal may improve oxygenation and accelerate removal of mechanical ventilation, but this ultrafiltration may, in turn, predispose patients to hypotension and secondary organ injury (53) . Furthermore, RRT has been presented with obstacles related to a state of hypercoagulability in severe COVID-19 cases that results in intra-and extracorporeal clotting events with subsequent early termination of treatment. Termination can reduce the gross quality of dialysis, metabolic imbalances, fluid overload J o u r n a l P r e -p r o o f increased blood loss due to more frequent changes in the system and is likely to promote further complications for patients. (55) . Therefore, specialists have acknowledged the urgent need to establish specific anticoagulation regimens in patients with COVID-19 requiring RRT (42, 55) . Nadim et al. has suggested the use of continuous veno-venous hemodialysis or continuous venovenous hemodialysis filtration to decrease filtration fraction and reduce the risk of circuit clotting if using CRRT (49) . Given that the optimal approach to COVID-19 related Kidney Injury treatment is still uncertain, decisions for RRT modalities and prescriptions remain largely dependent on clinical judgment and resources available. One avenue that can be explored for tailoring clinical interventions specific to patients includes the use of kidney biopsies, which would help understand the histological pattern of injury (tubular, glomerular, and vascular) and the pathogenesis that could lead to AKI (47) . In a case report of granulomatous interstitial nephritis, Szajek et al. described a SARS-CoV-2 positive patient with severe ARDS, multi-organ failure, developed oliguric AKI requiring analysis. Given the broad differential diagnoses for AKI, they performed a kidney biopsy that ultimately directed their treatment strategy. Based on findings, the decision was made to adjust medications, initiate corticosteroids, and his individually tailored clinical management plan resulted in recovery, discharge from rehabilitation, and no-longer required dialysis. This case highlights the significant value of kidney biopsies in clinical diagnoses and may impact patient outcomes if a treatable cause is identified. They also highlighted the more frequently recognized drug-interactions in COVID-19 that can potentially be reversible, given the correct histopathology is determined (56) . Unfortunately, various factors specific to COVID-19, including the respiratory and hemodynamic instability of AKI patients, anticoagulation that increases the risk of bleeding, makes obtaining kidney biopsies, and use of mechanical ventilation make obtaining kidney biopsies of suspected AKI patients very difficult. Additionally, the risk of exposure to hospital personnel has severely limited the non-essential procedures performed in infected patients (47, 49) . The use and criteria for warranted kidney biopsies are an important area that needs to be further evaluated and can potentially be informative in developing targeted biomarker therapies. Much is still unknown about the resultant impact of kidney dysfunction on mortality, but current research suggests the renal impairment in patients is associated with increased mortality. Additionally, COVID-19 patients with AKI or CKD exhibited greater in-hospital mortality, and the mortality rates between these two groups were comparable. Notably, the highest mortality rates were observed in patients who previously underwent renal transplant, with increased KDIGO stage associated with increased mortality, and significant proportions of these patients requiring RRT after discharge. debated, leading to providers needing to reduce dosages of immunosuppressants on a case-bycase basis carefully. Additionally, reports of AKI in transplant patients seem to be at a higher rate than the general population and are at a higher mortality rate from COVID-19. To date, there is no specific treatment for COVID-19 induced AKI, and management of COVID-19 associated AKI is generally similar to patients with AKI associated with other etiologies such as sepsis (45, 46) . Current management of COVID-19 associated AKI includes supportive treatment, avoiding nephrotoxic drugs, and, if possible, an early start of renal replacement therapy (47, 48) . Conservative management of volume overload, metabolic acidosis, and hyperkalemia can be attempted before considering initiation of kidney replacement therapy (KRT) (46) . Careful fluid management is important to consider as a modality to reduce the risk of non-cardiogenic pulmonary edema, commonly associated with ARDS (50) (51) (52) . SARS, MERS, and sepsis have been successfully treated in the past with continuous renal replacement therapy (CRRT). Therefore COVID-19 patients can benefit, although it needs to be evaluated more carefully and has many logistical limitations during the current pandemic, including transmission, lack of resources, and experienced personnel (47) . Specialists have also acknowledged the need to establish specific anticoagulation regimens in COVID-19 patients with a predisposition for hypercoagulability (42, 55) . Future research should include the use of kidney biopsies to elucidate the specific histopathology of a patient's AKI, the potential to target treatments, and the cost-benefit of performing these procedures in at-risk patient populations. The potential impact of SARS-CoV-2 on the kidneys is still undetermined. Still, emerging evidence indicates that kidney complications are frequent, and COVID-19 disease may have unique features in individuals on chronic dialysis and kidney transplant recipients, requiring increased vigilance in limiting viral transmission in perioperative, in-patient, and dialysis center settings (47) . Other authors report no conflicts of interest. No funding was received for this work. -Current evidence shows that acute kidney injury (AKI) in COVID-19 patients is as high as 25% and up to 60% patients experience proteinuria -Risk factors for severe COVID-19 infections and AKI are similar, including older age, diabetes mellitus, hypertension and cardiovascular disease. -AKI in COVID-19 patients may be associated with increased mortality, particularly in patients that require escalating treatment such as renal replacement therapy. -In-center hemodialysis may raise the risk of infection transmission due to their densely populated outpatient units. The management of these at-risk patients must follow stringent guidelines to reduce transmission risk to other patients and healthcare workers. J o u r n a l P r e -p r o o f -While some evidence sheds light on the multifactorial impact of COVID-19 on renal physiology, the definitive pathophysiologic mechanisms are yet to be defined. -Meta-analyses of emerging data will reveal the effect of AKI in the setting of COVID-19 on mortality. -The pandemic might boost home dialysis utilization, although clinical and economic implications are yet to be determined. -Future trials will clarify some controversial current guidelines on how to manage immunosuppression in kidney transplant patients with COVID-19. J o u r n a l P r e -p r o o f COVID-19 and the kidney: A matter of concern. Current Medicine Research and Practice COVID-19 and the Kidneys: An Update. Front Med The kidney and COVID-19 patients -Important considerations. Travel Medicine and Infectious Disease Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology COVID-19 and the Kidneys: An Update Nephrology O behalf of C-19 WG of IS of. COVID 19 and acute kidney injury Caution on Kidney Dysfunctions of COVID-19 Patients Social Science Research Network COVID-19 and the kidney: A matter of concern COVID-19 and the Kidneys: An Update. Front Med (Lausanne) COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection Collapsing Glomerulopathy in a Patient With COVID-19 Collapsing glomerulopathy in a COVID-19 patient Renal impairment and its impact on clinical outcomes in patients who are critically ill with COVID-19: a multicentre observational study Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease The Novel Coronavirus 2019 epidemic and kidneys Acute kidney injury in patients hospitalized with COVID-19 Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection [Internet]. medRxiv Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China Kidney Biopsy Findings in a Critically Ill COVID-19 Patient With Dialysis-Dependent Acute Kidney Injury: A Case Against "SARS-CoV-2 Nephropathy COVID-19 in Hemodialysis Patients: A Report of 5 Cases Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan Presentation and Outcomes of Patients with ESKD and COVID-19 COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Hemodialysis and COVID-19: An Achilles' Heel in the Pandemic Health Care Response in the United States. Kidney Medicine COVID-19 in dialysis patients: outlasting and outsmarting a pandemic COVID-19 in solid organ transplant recipients: Initial report from the US epicenter Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Covid-19 and Kidney Transplantation COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients COVID-19 in kidney transplant recipients COVID-19 infection in kidney transplant recipients. Kidney International Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Management of acute kidney injury in patients with COVID-19 The kidney and COVID-19 patients -Important considerations Caution on Kidney Dysfunctions of COVID-19 Patients Acute kidney injury in critically ill patients with COVID-19 Management of Acute Kidney Injury in Coronavirus Disease COVID-19 and the Kidneys: An Update. Front Med (Lausanne) Kidney disease is associated with in-hospital death of patients with COVID-19 COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup A Dramatic Presentation of Pulmonary Edema Due to Renal Failure Nephrogenic acute respiratory distress syndrome: A narrative review on pathophysiology and treatment Treatment for severe acute respiratory distress syndrome from COVID-19. The Lancet Respiratory Medicine COVID-19-Associated Acute Kidney Injury: Learning from the First Wave Acute Kidney Injury COVID-19 Treatment Guidelines Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study Granulomatous interstitial nephritis in a patient with SARS-CoV-2 infection Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers. Antimicrobial Resistance & Infection Control CDC. COVID-19 Cases, Deaths, and Trends in the US | CDC COVID Data Tracker COVID-19 and the kidney: A matter of concern Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention